Ligand Pharmaceuticals Incorporated
LGND
Classifica tra le azioni
#3114
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Prezzo delle azioni
$291.18
Ultima sincronizzazione: 2026-07-31
Capitalizzazione di mercato
$5.84B
Variazione (1 giorno)
-1.73%
Variazione (1 anno)
55.99%
Paese
US
Scambia Ligand Pharmaceuticals Incorporated (LGND)
Categoria
Healthcare
Rapporto P/E per Ligand Pharmaceuticals Incorporated (LGND)
Rapporto P/E al October 2026 TTM: 29.47
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Ligand Pharmaceuticals Incorporated, il rapporto P/E attuale (TTM) è 29.47. Alla fine del 2023, il rapporto P/E era 23.69.
Storico del rapporto P/E per Ligand Pharmaceuticals Incorporated da 2000 a 2026
Rapporto P/E alla fine di ogni anno
| Anno | Rapporto P/E | Cambia |
|---|---|---|
| 2026 (TTM) | 29.47 | -106.06% |
| 2024 | -486.05 | -2,151.90% |
| 2023 | 23.69 | -170.13% |
| 2022 | -33.78 | -175.13% |
| 2021 | 44.96 | -108.34% |
| 2020 | -539.23 | -17,229.80% |
| 2019 | 3.15 | -86.17% |
| 2018 | 22.77 | -90.07% |
| 2017 | 229.37 | -117.73% |
| 2016 | -1.29K | -15,615.10% |
| 2015 | 8.34 | -90.77% |
| 2014 | 90.36 | -3.41% |
| 2013 | 93.55 | -112.45% |
| 2012 | -751.68 | -3,378.49% |
| 2011 | 22.93 | -264.01% |
| 2010 | -13.98 | -88.91% |
| 2009 | -126.08 | 4,626.87% |
| 2008 | -2.67 | -258.53% |
| 2007 | 1.68 | -106.05% |
| 2006 | -27.81 | 96.61% |
| 2005 | -14.14 | -25.56% |
| 2004 | -19.00 | -31.44% |
| 2003 | -27.72 | 290.20% |
| 2002 | -7.10 | -53.97% |
| 2001 | -15.43 | 129.72% |
| 2000 | -6.72 | 0.00% |
Rapporto P/E per aziende simili o concorrenti
| Azienda | P/E Ratio | Differenza del P/E Ratio | Il paese |
|---|---|---|---|
| 28.78 | -2.33% |
US
|
|
| -28.36 | -196.23% |
US
|
|
| -24.57 | -183.36% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 2.92% |
NL
|
Come leggere un P/E ratio?
Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.
Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.
Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.